Retatrutide (LY3437943) is a single peptide that agonizes three receptors: glucagon, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Retatrutide' with aliases LY3437943 · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 04:00 · somebody
fact added summary: Retatrutide (LY3437943) is a single peptide that agonizes three receptors: glucagon, glucose-dependent insulinotropic po · 2026-09-27 04:00 · somebody
fact added mechanism: In obese mice, glucagon-receptor-driven increases in energy expenditure added to the reduced calorie intake driven by it · 2026-09-27 04:00 · somebody
fact added history: In a 48-week phase 2 trial of 338 adults with obesity, mean body weight fell by up to 24.2% on the highest dose, against · 2026-09-27 04:00 · somebody
citation added pmid 35985340 cited as emerging: Discovery and phase 1 proof of concept of the triple agonist LY3437943 · 2026-09-27 04:00 · somebody
citation added pmid 37366315 cited as emerging: Phase 2 randomized trial in obesity · 2026-09-27 04:00 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.